Table 1.

Summary of drugs studied in WHF with trials and their main findings.

Drug	Trials and Main Findings	Reference
Levosimendan	LevoRep trial: Intermittent Levosimendan infusion did not significantly improve patients’ functional capacity and quality of life.	[20]
	LION-HEART trial: Intermittent Levosimendan administration was effective in decreasing the serum concentration of NT-proBNP and was associated with improvement in clinical symptoms.	[21]
	LAICA study: Repetitive Levosimendan infusion is effective in reducing the HF hospitalization rate and HF worsening in patients with advanced HF.	[22]
	LeoDOR trial: Repetitive Levosimendan administration in patients with a recent HF hospitalization did not result in post-hospitalization clinical stability.	[23]
Vericiguat	VICTORIA trial: The primary composite of death from cardiovascular causes or first hospitalization for HF was lower in those who received Vericiguat.	[27]
Omecamtiv Mecarbil	GALACTIC-HF trial: The primary composite endpoint of hospitalization or urgent visit for HF and death from cardiovascular causes is reduced in patients treated with OM.	[34]
	METEORIC-HF trial: OM did not increase exercise capacity after 20 weeks of treatment.	[35]
	COSMIC-HF trial: Guiding the administration of OM through drug pharmacokinetic is associated with reduction in ventricular diameter and cardiac function improvement.	[33]
Sotagliflozin	SOLOIST-WHF trial: The primary endpoint, a combination of total number of cardiovascular deaths, hospitalizations and urgent visits for HF, resulted lower, and the benefits of an early initiation of Sotagliflozin, before or immediately after hospital discharge, was highlighted.	[38]
	SCORED trial: Sotagliflozin reduced the composite endpoint of HF hospitalization, urgent ambulatory visit and cardiovascular death, along with major incidence of adverse events.	[41]

WHF: worsening heart failure; NT proBNP: N-terminal pro B-type natriuretic peptide; HF: heart failure; OM: omecamtiv mecarbil.